Table 2.
Change from baseline at 18 months in measures of glucose control, insulin sensitivity, body weight, inflammatory/thrombotic markers and lipid measures
| Background metformin | Background sulphonylurea | |||||
|---|---|---|---|---|---|---|
| Background metformin | Background sulphonylurea | |||||
| Rosiglitazone | vs. | Sulphonylurea | Rosiglitazone | vs. | Metformin | |
| ITT population (n) | 253 | 263 | 301 | 272 | ||
| Completers (n) | 202 | 240 | 236 | 226 | ||
| HbA1c (%) | ||||||
| Change | −0.48 (−0.59, −0.36) | −0.55 (−0.66, −0.44) | −0.55 (−0.67, −0.44) | −0.61 (−0.70, −0.51) | ||
| Difference, P | 0.07 (−0.09, 0.23), NS | 0.06 (−0.09, 0.20), NS | ||||
| Fasting plasma glucose (mmol/l) | ||||||
| Change | −1.5 (−1.78, −1.29) | −1.2 (−1.46, −0.89) | −2.0 (−2.26, −1.66) | −1.6 (−1.87, −1.36) | ||
| Difference, P | −0.36 (−0.74, 0.02), 0.062 | −0.34 (−0.73, 0.05), 0.089 | ||||
| Homeostasis model assessment %B (% baseline) | ||||||
| Change | 13.4 (4.2, 23.3) | 38.8 (28.3, 50.1) | 33.0 (22.2, 44.7) | 25.4 (15.1, 36.6) | ||
| Difference, P | −18.3 (−27.2, −8.4), < 0.001 | 6.1 (−6.0, 19.7), NS | ||||
| Homeostasis model assessment %S (% baseline) | ||||||
| Change | 56 (42, 70) | 11 (2, 20) | 65 (53, 77) | 36 (26, 46) | ||
| Difference, P | 40 (25, 58), < 0.001 | 21 (10, 34), < 0.001 | ||||
| Body weight (kg) | ||||||
| Change | 2.3 (1.7, 2.9) | 1.1 (0.6, 1.6) | 3.4 (2.9, 4.0) | −0.9 (−1.4, −0.4) | ||
| Difference, P | 1.2 (0.4, 2.0), 0.003 | 4.3 (3.6, 5.1), < 0.001 | ||||
| C-reactive protein (% baseline) | ||||||
| Change | −41 (−48, −33) | −6 (−17, 6) | −36 (−43, −28) | −16 (−26, −6) | ||
| Difference, P | −37 (−47, −24), < 0.001 | −24 (−35, −10), 0.001 | ||||
| Plasminogen activator inhibitor-1 antigen (% baseline) | ||||||
| Change | −5.7 (−13.9, 3.3) | 7.0 (−1.7, 16.4) | −11.1 (−18.5, −3.1) | −11.2 (−18.7, −3.0) | ||
| Difference, P | −12 (−22, −0.2), 0.047 | 0 (−12, 13), NS | ||||
| Fibrinogen (% baseline) | ||||||
| Change | 2.1 (−0.9, 5.1) | 10.9 (7.9, 14.0) | 3.2 (0.9, 5.7) | 7.3 (4.7, 9.9) | ||
| Difference, P | −8.0 (−11.6, −4.2), 0.001 | −3.8 (−7.0, −0.5), 0.024 | ||||
| Total cholesterol (mmol/l) | ||||||
| Change | 0.37 (0.23, 0.51) | −0.16 (−0.29, −0.03) | 0.46 (0.33, 0.59) | −0.10 (−0.24, 0.04) | ||
| Difference, P | 0.53 (0.34, 0.71), < 0.001 | 0.56 (0.36, 0.75), 0.001 | ||||
| Triglycerides (mmol/l) | ||||||
| Change | 0.40 (0.25, 0.55) | 0.15 (0.01, 0.29) | 0.24 (0.06, 0.42) | 0.17 (−0.02, 0.36) | ||
| Difference, P | 0.26 (0.05, 0.47), 0.016 | 0.06 (−0.20, 0.32), NS | ||||
| High-density lipoprotein cholesterol (mmol/l) | ||||||
| Change | 0.08 (0.05, 0.11) | 0.02 (−0.01, 0.05) | 0.10 (0.07, 0.13) | 0.08 (0.05, 0.11) | ||
| Difference, P | 0.06 (0.02, 0.10), 0.001 | 0.01 (−0.02, 0.05), NS | ||||
| Low-density lipoprotein cholesterol (mmol/l) | ||||||
| Change | 0.04 (−0.07, 0.15) | −0.26 (−0.36, −0.16) | 0.19 (0.08, 0.30) | −0.29 (−0.40, −0.18) | ||
| Difference, P | 0.30 (0.16, 0.45), 0.000 | 0.48 (0.32, 0.64), 0.000 | ||||
| Non-esterified fatty acids (mmol/l) | ||||||
| Change | −0.07 (−0.10, −0.04) | 0.04 (0.01, 0.07) | −0.06 (−0.10, −0.02) | 0.06 (0.02, 0.10) | ||
| Difference, P | −0.11 (−0.15, −0.06), 0.000 | −0.12 (−0.17, −0.07), 0.000 | ||||
Data are model-adjusted mean (95% CI), or number.